Oncology

Category

OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites

The cancer research as a care option movement gains considerable momentum in the United States with the recent formation of a partnership between OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX:...

University of Louisville’s Brown Cancer Center Embraces Immuno-Oncology Developed at NCI: Some Patients See Dramatic Results

A 46 year-old man residing in the Louisville, Kentucky area was given about six months to live, according to a physician’s grim forecast. With stage four lung cancer that August, Tony Burton’s options for life narrowed but he sought out a second opinion with Dr. Jason...

Cancer Clinical Trials As-Care-Option Moves into Western North Carolina via Messino Cancer Centers & Sarah Cannon Research Institute Partnership

The clinical research as a care option movement advances with yet another important but not well publicized deal involving Messino Cancer Centers (MCC), a partner practice of American Oncology Network, LLC (AON) and the Sarah Cannon Research Institute, a global leader...

Southeast Nebraska Cancer Center Joints Elite NCI Cancer Networks to Offer State-of-Art Clinical Trials to Nebraskan Cancer Patients

The Southeast Nebraska Cancer Center (SNCC) brings the clinical research as a care option movement to Lincoln, Nebraska, and more generally the eastern regions of the state. By offering local patients with advanced oncologic and hematologic diagnoses comprehensive,...

SWOG Cancer Research Network Deepens Ties into Veterans Administration for More Clinical Research as a Care Option Access

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announced the award of two grants designed to give military veterans better access to cancer clinical trials. Under the VA Integration Support Program, U.S. Department of Veterans...

Pierre Fabre Initiates a “First in Human” Clinical Trial for an Innovative Monoclonal Antibody (W0180) Targeting the VISTA Checkpoint in Patients with Solid Tumors

Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care...